AEterna Zentaris (AEZS) +4.8% premarket after announcing the FDA supports a phase 3 trial of its...

|About: AEterna Zentaris, Inc. (AEZS)|By:, SA News Editor

AEterna Zentaris (AEZS) +4.8% premarket after announcing the FDA supports a phase 3 trial of its drug AEZS-108, a potential treatment for endometrial cancer. A "special protocol assessment" agreement says the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.